Top Markets
#1 龙虾 (Lobster) 龙虾 (Lobster) +37.09%
#2 Cortex Cortex +32.82%
#3 DexNet DexNet +23.20%
#4 wojak wojak +20.40%
#5 Akedo Akedo +20.04%
#6 Pons Pons +19.43%
#7 OpenEden OpenEden +14.81%
#8 APEX APEX +13.93%
#9 TDCCP TDCCP +11.15%
#10 The Black Bull The Black Bull +9.95%
Coin of the day
龙虾 (Lobster) 龙虾 (Lobster)
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
HBM Holdings Limited HBM Holdings Limited

HBM Holdings Limited

2142
Classifica tra le azioni #7297
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused... HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising assets. In immunology, Batoclimab (HBM9161) is a human monoclonal antibody specifically designed to bind and inhibit the neonatal fragment crystallizable receptor, while Tanfanercept (HBM9036) is under development to address moderate to severe dry eye disease. For oncology, HBM Holdings is advancing various therapies, such as HBM7008, a bispecific antibody targeting tumor-associated antigens, and HBM4003, a human anti-CTLA-4 antibody. Additional cancer candidates in their portfolio include HBM9302 for breast and gastric cancers, HBM7020 for multiple myeloma, and a suite of treatments—HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022—geared towards solid tumors. Furthermore, HBM9022 is being developed to treat SARS-COV-2. Operating globally, HBM Holdings has a presence in Mainland China, the United States, Europe, and other international markets. The company also fosters strategic partnerships for antibody-drug conjugate (ADC) projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was founded in 2016 and is based in Shanghai, People's Republic of China.
Prezzo delle azioni
$1.95
Capitalizzazione di mercato
$1.64B
Variazione (1 giorno)
-6.69%
Variazione (1 anno)
19.42%
Paese
CN
Scambia HBM Holdings Limited (2142)

Categoria

Healthcare
EPS per HBM Holdings Limited (2142)
EPS al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di HBM Holdings Limited, l’EPS attuale della società (TTM) è 0. Alla fine del 2026, la società aveva un EPS di 0 uguale a rispetto a quello del 2026, che era di 0.
Storico EPS per HBM Holdings Limited da 2026 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
Non abbastanza dati per le date fornite.
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH